Delivery Order SPE2DB25D3018-SPE2DB25FUYGR
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $53,836.52 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded delivery order represents a pharmaceutical supply fulfillment under the company's broader federal contract portfolio. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,570.66 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $1 billion and runs...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,218.76 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors. The contract, awarded July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYGRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,573.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL quantity). This non-competitive, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying medications and medical commodities to military and veteran healthcare systems through the DLA's Medical Supply Chain. Dupixent (dupilumab) is a specialized biologic immunosuppressant medication used to treat moderate-to-severe atopic dermatitis and other immune-related conditions. The supply of this medication supports the Defense Health Agency and broader Department of Defense healthcare programs. AmerisourceBergen's federal contract portfolio demonstrates its established capability to deliver specialty pharmaceuticals and medical supplies through competitive procurement processes, with consistent use of firm fixed-price delivery order structures across its DLA contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/18/25 |